Last reviewed · How we verify
NCT05993429
Diagnostic Efficacy of EUS-FNA/B Versus ERCP With or Without POCS-TB in Patients With Suspected Hilar Cholangiocarcinoma
trial testing The sampling method selected in patients with suspected hilar cholangiocarcinoma in Klatskin Tumor in 200 participants. Completed in 31 December 2025.
31 December 2025
Quick facts
| Lead sponsor | Qilu Hospital of Shandong University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 14 August 2023 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- The sampling method selected in patients with suspected hilar cholangiocarcinoma
Conditions studied
- Klatskin Tumor — all drugs for Klatskin Tumor →
- Cholangiocarcinoma — all drugs for Cholangiocarcinoma →
- Biopsy, Fine-Needle — all drugs for Biopsy, Fine-Needle →
- Endoscopic Retrograde Cholangiopancreatography — all drugs for Endoscopic Retrograde Cholangiopancreatography →
Sponsor
Qilu Hospital of Shandong University
Who can join
Eligibility, any sex, with Klatskin Tumor or Cholangiocarcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an observational study with a prospective cohort design. This study enrolled patients with suspected hilar cholangiocarcinoma on imaging. This study aims to evaluate the histopathological diagnostic efficacy of endoscopic ultrasound-guided fine-needle aspiration/biopsy (EUS-FNA/B) and endoscopic retrograde cholangiopancreatography (ERCP) with or without peroral cholangioscopy targeted biopsy (POCS-TB) in patients with suspected hilar cholangiocarcinoma. In addition, the incidence of complications was compared between the EUS-FNA/B and ERCP with or without POCS-TB. The impact of the histopathological diagnosis on survival outcomes in patients with suspected hilar cholangiocarcinoma was evaluated.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05993429
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Klatskin Tumor
Currently open trials in the same condition.
- NCT06986486 — Liver Transplantation for Unresectable Perihilar Cholangiocarcinoma · recruiting
- NCT06493734 — Stereotactic Body Radiation Therapy After Chemotherapy for Unresectable Perihilar Cholangiocarcinoma · NA · recruiting
- NCT06964425 — Raman Spectroscopy in the Diagnosis of Extrahepatic Cholangiocarcinoma - a Pilot Study · NA · recruiting
- NCT04993131 — Liver Transplantation for Non-resectable Perihilar Cholangiocarcinoma · NA · recruiting
Other Qilu Hospital of Shandong University trials
Trials by the same sponsor.
- NCT06704074 — Virtual Reality Task Oriented Training on Upper Limb Function in Stroke Patients · NA · recruiting
- NCT07140419 — Coronary Computed Tomographic Angiography Combined With CT-FFR in Intermediate-Risk Chest Pain Patients. · NA · not yet recruiting
- NCT07509879 — Research on the Molecular Mechanism of Cognitive Differences Between Williams Syndrome and Autism Spectrum Disorder · not yet recruiting
- NCT07537374 — A Case-Control Observational Study of Peripheral Blood-Derived iPSC Models to Investigate Oligodendrocyte Lineage Develo · not yet recruiting
- NCT07505940 — Bilateral Comparison of Unilateral Sacral Neuromodulation Test Stimulation in the Treatment of Neurogenic Bladder · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05993429 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Qilu Hospital of Shandong University
- Last refreshed: 26 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05993429.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing